Works matching IS 00070963 AND DT 2024 AND VI 191 AND IP 3


Results: 40
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa.

    Published in:
    British Journal of Dermatology, 2024, v. 191, n. 3, p. 463, doi. 10.1093/bjd/ljae200
    By:
    • Korte, Eva W H;
    • Pasmooij, Anna M G;
    • Bolling, Maria C;
    • Hickey, Sinéad;
    • Hussain, Sagair;
    • Kiritsi, Dimitra;
    • Kottner, Jan;
    • Prinsen, Cecilia A C;
    • Sauvestre, Angélique;
    • Sendin, Gaston;
    • Spuls, Phyllis I;
    • Tarrats, Núria;
    • Wally, Verena;
    • Welponer, Tobias;
    • Laimer, Martin;
    • Akker, Peter C van den;
    • COSEB Consortium, the
    Publication type:
    Article
    12

    MiTES: itch or pain?

    Published in:
    British Journal of Dermatology, 2024, v. 191, n. 3, p. 323, doi. 10.1093/bjd/ljae198
    By:
    • Has, Cristina
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20
    21

    De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study.

    Published in:
    British Journal of Dermatology, 2024, v. 191, n. 3, p. 460, doi. 10.1093/bjd/ljae184
    By:
    • Tang, Kimberly;
    • Rajeh, Ahmad;
    • Shaw, Katharina S;
    • Nguyen, Nga;
    • Wan, Guihong;
    • Hashemi, Kimberly B;
    • Castillo, Rochelle L;
    • Kwatra, Shawn G;
    • LeBoeuf, Nicole R;
    • Vleugels, Ruth Ann;
    • Semenov, Yevgeniy R
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29

    Midfacial toddler excoriation syndrome (MiTES): case series, diagnostic criteria and evidence for a pathogenic mechanism.

    Published in:
    British Journal of Dermatology, 2024, v. 191, n. 3, p. 437, doi. 10.1093/bjd/ljae151
    By:
    • Sarveswaran, Nivedita;
    • Pamela, Yunisa;
    • Reddy, Akhila A N;
    • Mustari, Akash P;
    • Parthasarathi, Anchala;
    • Mancini, Anthony J;
    • Bishnoi, Anuradha;
    • Inamadar, Arun C;
    • Olabi, Bayanne;
    • Browne, Fiona;
    • Deshmukh, Gargi N;
    • McWilliam, Kenneth;
    • Vinay, Keshavamurthy;
    • Srinivas, Sahana;
    • Ibbs, Samantha;
    • Natarajan, Sivakumar;
    • Rao, Vadlamudi R;
    • Zawar, Vijay;
    • Gowda, Vykuntaraju K;
    • Shaikh, Samiha S
    Publication type:
    Article
    30
    31
    32
    33

    Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study.

    Published in:
    British Journal of Dermatology, 2024, v. 191, n. 3, p. 419, doi. 10.1093/bjd/ljae152
    By:
    • Mitsunaga, Keila;
    • Bagot, Martine;
    • Ram-Wolff, Caroline;
    • Guenova, Emmanuella;
    • Gugelberg, Christina von;
    • Hodak, Emmilia;
    • Amitay-Laish, Iris;
    • Papadavid, Evangelia;
    • Jonak, Constanze;
    • Porkert, Stefanie;
    • Scarisbrick, Julia;
    • Applewaite, Rona;
    • Beylot-Barry, Marie;
    • Nicolay, Jan;
    • Quaglino, Pietro;
    • Sanches, José Antonio;
    • Cury-Martins, Jade;
    • Lora-Pablos, David;
    • Ortiz, Pablo
    Publication type:
    Article
    34
    35
    36
    37

    A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.

    Published in:
    British Journal of Dermatology, 2024, v. 191, n. 3, p. 336, doi. 10.1093/bjd/ljae062
    By:
    • Cai, Lin;
    • Jiang, Congjun;
    • Zhang, Guoqiang;
    • Fang, Hong;
    • Wang, Jinyan;
    • Li, Yumei;
    • Xu, Hui;
    • Xiao, Rong;
    • Ding, Yangfeng;
    • Huang, Kun;
    • Zhang, Chunlei;
    • Zhang, Litao;
    • Chen, Bin;
    • Duan, Xinsuo;
    • Pan, Weili;
    • Han, Guangming;
    • Chen, Rongyi;
    • Liu, Lunfei;
    • Zhang, Shoumin;
    • Tao, Juan
    Publication type:
    Article
    38
    39
    40